Evidence‑Based Priorities in Lipid Management

Primary Lipid Targets

LDL‑C reduction is the principal evidence‑based goal for cardiovascular risk reduction; statin therapy lowers cardiovascular events by approximately 22 % for each 39 mg/dL (≈1 mmol/L) decrease in LDL‑C (Circulation 2020) 1.
Therapies that raise HDL‑C alone have not demonstrated sufficient risk‑reduction benefit to justify setting specific HDL‑C targets (Arteriosclerosis, Thrombosis, and Vascular Biology 2004) [2][3].

Fenofibrate, especially when combined with a statin, is more effective at increasing HDL‑C than gemfibrozil and carries a lower risk of statin‑associated myopathy (Arteriosclerosis, Thrombosis, and Vascular Biology 2004) [2][3].
Nicotinic acid (niacin) added to statin therapy produces the greatest HDL‑C elevations, but in patients with diabetes it can markedly worsen hyperglycemia; dosing should be limited to ≤2 g/day with frequent glucose monitoring (Arteriosclerosis, Thrombosis, and Vascular Biology 2004; Diabetes Care 2003) [3][4].
Comprehensive lifestyle modification—including weight loss, regular aerobic exercise, and smoking cessation—can modestly raise HDL‑C and should be employed alongside pharmacologic therapy (Diabetes Care 2004) 5.

Statins should not be prescribed primarily to raise HDL‑C; their principal benefit derives from LDL‑C lowering (Arteriosclerosis, Thrombosis, and Vascular Biology 2004) [2][3].
Increasing statin dose does not reliably increase HDL‑C, although higher doses may modestly lower triglycerides (Diabetes Care 2003) 4.
When combining a fibrate with a statin, fenofibrate is preferred over gemfibrozil because it does not interfere with statin metabolism and thus reduces myopathy risk (Arteriosclerosis, Thrombosis, and Vascular Biology 2004) 2.
In diabetic patients, niacin should be used cautiously due to its potential to exacerbate hyperglycemia; close monitoring of blood glucose is essential (Diabetes Care 2003) 4.

The American College of Cardiology recommends that pravastatin and lovastatin produce modest HDL-C increases, but are less potent than rosuvastatin or pitavastatin 6, 7
The American College of Cardiology states that fluvastatin demonstrates minimal HDL-raising effects 6, 7

The American Diabetes Association notes that statins are primarily LDL-lowering agents, and their HDL-raising effects are modest, typically 5-10% 8, 9, 10
The American College of Cardiology recommends that for patients requiring significant HDL elevation, fibrates or niacin are more effective, though these lack the cardiovascular outcomes data that statins possess 11, 8, 9
The American College of Cardiology suggests that when statin monotherapy fails to adequately raise HDL-C, combination with fenofibrate is more effective than gemfibrozil 8, 12, 13
The American Diabetes Association advises that niacin combined with statins produces the largest HDL-C increases, but requires caution in diabetic patients due to glycemic effects 8, 9, 10

The American College of Cardiology warns that relying solely on HDL-C elevation for cardiovascular risk reduction is not recommended, as LDL-C lowering remains the primary evidence-based target for cardiovascular outcomes 6, 7, 14
The American Diabetes Association recommends that lifestyle modifications, such as weight loss, increased physical activity, and smoking cessation, can increase HDL-C and should be implemented alongside pharmacotherapy 8, 9, 10, 13